Clinical TrialJun 30, 2026, 05:02 PM
Catalyst Pharma's Vamorolone Phase 1 Shows Balanced Corticosteroid Activity
AI Summary
Catalyst Pharmaceuticals announced positive topline results from a two-part Phase 1 clinical study of vamorolone in healthy adult volunteers. The study demonstrated balanced corticosteroid activity with expected cortisol suppression and no evidence of significant immunosuppressive activity at clinical doses. These findings suggest vamorolone delivers glucocorticoid and anti-inflammatory activity while avoiding significant immunosuppressant effects, supporting its potential use across a broad range of chronic inflammatory rare diseases.
Key Highlights
- Vamorolone Phase 1 study showed on-target glucocorticoid activity without significant immunosuppression at clinical doses.
- Part A compared single doses of vamorolone (300 mg) and deflazacort (0.9 mg/kg) in 24 healthy adults.
- Both agents demonstrated similar cortisol suppression and on-target glucocorticoid receptor activity.
- Vamorolone showed less pronounced immunosuppressive biomarker effects compared to deflazacort.
- Part B evaluated vamorolone at 9, 27, or 40 mg/kg once daily for seven days in 36 healthy volunteers.
- Clinically relevant immunosuppressive effects were observed only at the highest dose (40 mg/kg/day).
- No relevant immunosuppressive effects were observed at lower doses (9 or 27 mg/kg/day).
Price Impact
More from CPRX